Our Indications
Parkinson’s Disease
Zhittya Genesis Medicine has been developing a potential treatment for Parkinson’s disease following positive animal data in mice and monkeys. Since then Zhittya has been conducting medical research studies with humans having dosed 196 patients as of November 2024, where the average patient reported a 53% improvement in motor scores. Zhittya is hoping to start US FDA Clinical Trials in the coming years.
Coronary Artery Disease
Zhittya Genesis Medicine has had positive US FDA Clinical Trial data indicating that FGF-1 may be a potential treatment for Coronary Artery Disease. In US FDA Phase IIA Clinical Trials, FGF-1 demonstrated that it could be a safe and efficacious treatment by growing around blocked arteries to treat heart disease in 16 patients.
Diabetic Foot Ulcers
In previous Phase II USA FDA clinical trials, Zhittya Genesis Medicine established that FGF-1 is a potent healer of diabetic foot ulcers, accelerating their healing, and, in one study, completely healing 100% of the ulcers treated with no adverse events noted.
Autism Spectrum Disorders
Recent research indicates that a vascular problem may exist in individuals suffering from autism, particularly as it pertains to the brain’s inability to grow new blood vessels. The lack of sufficient angiogenesis could lead to a decrease in capillary and arteriole density in important areas of the brain. Zhittya believes that FGF-1, a potent angiogenic factor could be a potential solution.
Diseases of Memory
Recent medical research has shown that the first initating event in diseases of memory such as Alzheimer’s Disease, Vascular Dementia, and others is vascular disorder within the brain. Zhittya Genesis Medicine believes that it’s drug, when utilized in the early stages of these diseases could, via angiogenesis, re-establish vascular order in the brain.
Stroke Recovery
In animal models of stroke, Zhittya Genesis medicine has been able to re-establish blood perfusion to areas of the brain that were damaged by the stroke, treating animal models with the disease almost entirely.
Diabetes
In January 2022, researchers at the Salk Institute discovered that FGF-1 can regulate blood glucose levels by inhibiting fat breakdown, offering a potential new treatment pathway for diabetes. This mechanism operates independently of insulin, suggesting that FGF-1 could be effective in patients with insulin resistance. Additionally, a 2017 review by the Howard Hughes Institute, highlighted FGF1's ability to restore normal blood sugar levels without significant adverse effects, further supporting its potential as a therapeutic agent for type 2 diabetes. Zhittya is now exploring the possibility of using FGF-1 to treat Diabetes.